Ongoing trials of intratumoural therapies for non-small cell lung cancer listed on

TherapyPhaseSiteTumour typesKey outcome(s) IDTitle
AdV-tk (aglatimagene besadenovec)+valacyclovirIIntratumoural bronchoscopic injectionNSCLCPrimary: Safety
Secondary: Immunologic changes, PFS, OS
NCT03131037Intratumoural gene-mediated cytotoxic immunotherapy in patients with resectable NSCLC
CCL21 gene-modified dendritic cell with pembrolizumabIBronchoscopic or CT-guided intratumoural injectionNSCLCPrimary: Maximum tolerated dose, objective response rate
Secondary: Adverse events, PD-L1 expression
NCT03546361Intratumoural administration of CCL21 gene-modified dendritic cell with intravenous pembrolizumab for advanced NSCLC
Intratumoural G100 with atezolizumab and radiotherapyIIIntratumoural bronchoscopic injectionNSCLC
Pancreatic cancer
Virus-associated tumours
Bladder cancer
Triple-negative breast cancer
Primary: Response by RECIST 1.1
Secondary: Adverse events, tumour immune cells, blood cytokines, lymphocytes and kynurenine
NCT03915678Atezolizumab combined with intratumoural G100 And immunogenic radiotherapy in patients with advanced solid tumours (AGADIR)
Intratumoural ilixadencel with pembrolizumabI/IIIntratumoural#NSCLC
Squamous cell carcinoma of head and neck
Gastric adenocarcinoma
Primary: Adverse events, objective response rate
Secondary: Objective response rate, CD8 T cell response by flow cytometry, overall survival, progression free survival
NCT03735290Study to evaluate the safety and effectiveness of ilIxadencel administered into tumours in combination with checkpoint inhibitor in patients with advanced cancer (ILIAD)
Oncolytic adenovirus (CAdVEC) and T cells (HER2-AdVST)IIntratumoural#Lung cancer
Bladder cancer
Squamous cell carcinoma of head and neck
Cancer of the salivary gland
Breast cancer
Gastric cancer
Oesophageal cancer
Colorectal cancer
Pancreatic adenocarcinoma
Primary: Maximum tolerated dose
Secondary: Response by RECIST 1.1, PFS, OS, adverse events
NCT03740256Binary oncolytic adenovirus in combination with HER2-specific chimeric antigen receptor modified cytotoxic T cells in advanced HER2 positive solid tumours (VISTA)
INT230-6I/IIIntratumoural#Lung cancer
Head and neck cancer
Breast cancer
Pancreatic cancer
Liver cancer
Colon cancer
Bile duct cancer
Ovarian cancer
Squamous cell carcinoma
Primary: Adverse events
Secondary: Efficacy, pharmacokinetics and pharmacodynamics
NCT03058289Phase 1/2 safety study of intratumourally dosed INT230-6 (IT-01)
Intratumoural ABBV-927 with or without ABBV-181IIntratumoural#NSCLC
Squamous cell carcinoma of head and neck
Advanced solid tumours
Primary: Maximum tolerated dose, pharmacokinetics and pharmacodynamics
Secondary: Clinical benefit rate, objective response rate, PFS
NCT02988960Study of ABBV-927 and ABBV-181, an immunotherapy, in subjects with advanced solid tumours
Clostridium novyi-NTIIntratumoural#Advanced solid tumoursPrimary: Maximum tolerated dose
Secondary: Response by RECIST 1.1
NCT03435952Pembrolizumab with intratumoural injection of Clostridium novyi-NT

NSCLC: non-small cell lung cancer; PFS: progression-free survival; OS: overall survival; RECIST: Response Evaluation Criteria In Solid Tumours. #: Method of intratumoural injection not specified or includes percutaneous injection.